Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis

Reproductive Sciences

Volumn 18, Issue 7, 2011, Pages 614-622

  Ricci, Analía Gabriela ^a   Olivares, Carla Noemí ^a   Bilotas, Mariela Andrea ^a   Meresman, Gabriela Fabiana ^a   Barañao, Rosa Inés ^a  

^a INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

Author keywords

apoptosis; BALB c mice; bevacizumab; cell proliferation; endometriosis

Indexed keywords

BEVACIZUMAB; CD34 ANTIGEN; CYCLINE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DENSITY; ENDOMETRIOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NICK END LABELING; NONHUMAN; PERITONEAL FLUID; PRIORITY JOURNAL; VASCULAR DENSITY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; ASCITIC FLUID; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOMETRIOSIS; FEMALE; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PROLIFERATING CELL NUCLEAR ANTIGEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959522400     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719110395406     Document Type: Article

References (46)

1. Galle PC. Clinical presentation and diagnosis of endometriosis. Obstet Gynecol Clin North Am. 1989 ; 16 (1). 29-42 (Pubitemid 19054702)
2. Rawson JM. Prevalence of endometriosis in asymptomatic women. J Reprod Med. 1991 ; 36 (7). 513-515
3. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009 ; 15 (4). 441-461
4. Mihalyi A, Simsa P, Mutinda KC, Meuleman C, Mwenda JM, D'Hooghe TM. Emerging drugs in endometriosis. Expert Opin Emerg Drugs. 2006 ; 11 (3). 503-524 (Pubitemid 44386373)
5. Valle RF, Sciarra JJ. Endometriosis: treatment strategies. Ann N Y Acad Sci. 2003 ; 997 (52). 229-239 (Pubitemid 38491079)
6. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci. 2002 ; 955 (26). 89-100 (Pubitemid 34271066)
7. McLaren J, Prentice A, Charnock-Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod. 1996 ; 11 (1). 220-223 (Pubitemid 26047702)
8. Bourlev V, Volkov N, Pavlovitch S, Lets N, Larsson A, Olovsson M. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction. 2006 ; 132 (3). 501-509 (Pubitemid 44524514)
9. Takehara M, Ueda M, Yamashita Y, Terai Y, Hung YC, Ueki M. Vascular endothelial growth factor A and C gene expression in endometriosis. Hum Pathol. 2004 ; 35 (11). 1369-1375 (Pubitemid 39601577)
10. McLaren J, Prentice A, Charnock-Jones DS, et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest. 1996 ; 98 (2). 482-489 (Pubitemid 26255749)
11. Hull ML, Charnock-Jones DS, Chan CL, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab. 2003 ; 88 (6). 2889-2899 (Pubitemid 36733546)
12. Nap AW, Griffioen AW, Dunselman GA, et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab. 2004 ; 89 (3). 1089-1095 (Pubitemid 38368395)
13. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997 ; 57 (20). 4593-4599 (Pubitemid 27441066)
14. Grothey A, Ellis LM. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J. 2008 ; 14 (3). 170-177
15. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005 ; 333 (2). 328-335 (Pubitemid 40848295)
16. Bilotas M, Meresman G, Stella I, Sueldo C, Baranao RI. Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis. Fertil Steril. 2010 ; 93 (8). 2513-2518
17. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007 ; 48 (6). 2545-2552 (Pubitemid 351261204)
18. Brodie A, Jelovac D, Long BJ. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clin Cancer Res. 2003 ; 9 (1). 455S - 459S (Pubitemid 36105787)
19. Meresman GF, Vighi S, Buquet RA, Contreras-Ortiz O, Tesone M, Rumi LS. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril. 2000 ; 74 (4). 760-766
20. Celik O, Hascalik S, Elter K, Tagluk ME, Gurates B, Aydin NE. Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways. Hum Reprod. 2008 ; 23 (11). 2458-2465
21. Rice VM. Conventional medical therapies for endometriosis. Ann N Y Acad Sci. 2002 ; 955 (1). 343-352 (Pubitemid 34271092)
22. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000 ; 52 (2). 237-268 (Pubitemid 30368433)
23. Groothuis PG, Nap AW, Winterhager E, Grummer R. Vascular development in endometriosis. Angiogenesis. 2005 ; 8 (2). 147-156 (Pubitemid 41712844)
24. Goss PE, Strasser-Weippl K. Prevention strategies with aromatase inhibitors. Clin Cancer Res. 2004 ; 10 (1). 372S - 379S (Pubitemid 38116645)
25. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002 ; 29 (6). 10-14
26. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995 ; 95 (16). 1789-1797
27. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res. 1995 ; 55 (22). 5296-5301
28. Mu J, Abe Y, Tsutsui T, et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn J Cancer Res. 1996 ; 87 (9). 963-971 (Pubitemid 26328923)
29. Cheng SY, Huang HJ, Nagane M, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A. 1996 ; 93 (16). 8502-8507 (Pubitemid 26269588)
30. Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod. 2006 ; 21 (1). 262-268 (Pubitemid 41794320)
31. Park A, Chang P, Ferin M, Xiao E, Zeitoun K. Inhibition of endometriosis development in rhesus monkeys by blocking VEGF receptor: A novel treatment for endometriosis. Fertility and Sterility. 2004 ; 82 (2). S71 - S71
32. Becker CM, Sampson DA, Rupnick MA, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril. 2005 ; 84 (suppl 2). 1144-1155 (Pubitemid 41396540)
33. Novella-Maestre E, Carda C, Noguera I, et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod. 2009 ; 24 (5). 1025-1035
34. Tariverdian N, Siedentopf F, Rucke M, et al. Intraperitoneal immune cell status in infertile women with and without endometriosis. J Reprod Immunol. 2009 ; 80 (1-2). 80-90
35. Tariverdian N, Theoharides TC, Siedentopf F, et al. Neuroendocrine-immune disequilibrium and endometriosis: an interdisciplinary approach. Semin Immunopathol. 2007 ; 29 (2). 193-210 (Pubitemid 47596400)
36. Somigliana E, Vigano P, Gaffuri B, et al. Modulation of NK cell lytic function by endometrial secretory factors: potential role in endometriosis. Am J Reprod Immunol. 1996 ; 36 (5). 295-300 (Pubitemid 26383982)
37. Moberg C, Catalano RD, Charnock-Jones DS, Olovsson M. VEGF-A and serum withdrawal induced changes in the transcript profile in human endometrial endothelial cells. Reprod Sci. 2010 ; 17 (6). 590-611
38. Bilotas M, Meresman G, Buquet R, Sueldo C, Baranao RI. Effect of vascular endothelial growth factor and interleukin-1beta on apoptosis in endometrial cell cultures from patients with endometriosis and controls. J Reprod Immunol. 2010 ; 84 (2). 193-198
39. Ge YL, Zhang X, Zhang JY, Hou L, Tian RH. The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells. Int Immunopharmacol. 2009 ; 9 (4). 389-395
40. Carneiro A, Falcao M, Pirraco A, Milheiro-Oliveira P, Falcao-Reis F, Soares R. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res. 2009 ; 88 (3). 522-527
41. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004 ; 7 (4). 335-345 (Pubitemid 40767935)
42. Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008 ; 49 (2). 522-527
43. Nakamura M, Abe Y, Tokunaga T. Pathological significance of vascular endothelial growth factor A isoform expression in human cancer. Pathol Int. 2002 ; 52 (5-6). 331-339 (Pubitemid 34748215)
44. McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet. 2003 ; 361 (9373). 1959
45. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007 ; 96 (12). 1788-1795 (Pubitemid 46912024)
46. Laschke MW, Menger MD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update. 2007 ; 13 (4). 331-342 (Pubitemid 47062827)